# Regeneron's Eylea and itepekimab failed to reach the required threshold for statistical significance.

*biotech · news · 2026-05-18 · MarketScreener*

## Key points

- Regeneron's combination therapy failed to achieve statistical significance against Merck's Keytruda in a key trial.
- Their planned Eylea pre-filled treatment faces regulatory delays, adding to recent setbacks.
- A new partnership with Parabilis Medicines could involve up to $2.2 billion in milestone payments.
- Analysts warn that repeated failures heighten pressure on Regeneron's late-stage pipeline in the next 12–18 months.
- Regeneron will pursue another trial comparing their therapy to Bristol Myers Squibb's Opdualag despite increased caution.

**Companies:** Merck, Regeneron, Bristol Myers Squibb

[Read the full story on MarketScreener](https://www.marketscreener.com/news/regeneron-hit-by-advanced-melanoma-treatment-failing-trial-ce7f5adadf8ff02d)

---

Canonical: https://newsio.io/n/06b8c7ef-c031-4d71-98a5-37a9e79bb80f/regenerons-eylea-and-itepekimab-failed-to-reach-the-required-threshold-for-stati
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works